• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of tenoxicam in patients with impaired renal function.

作者信息

Horber F F, Guentert T W, Weidekamm E, Heizmann P, Descoeudres C, Frey F J

出版信息

Eur J Clin Pharmacol. 1986;29(6):697-701. doi: 10.1007/BF00615961.

DOI:10.1007/BF00615961
PMID:3709612
Abstract

The pharmacokinetics of tenoxicam after a single oral dose of 20 mg has been studied in 12 patients with various degrees of decreased renal function. Unchanged tenoxicam and its 5'OH-metabolite in plasma and urine were determined by HPLC. The mean areas under the plasma concentration-time curve (138 +/- 53 micrograms/ml X h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam. The half-life of 5'OH-tenoxicam and unchanged tenoxicam where the same. The urinary excretion of 5'OH-tenoxicam fell with decreasing renal function. Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure.

摘要

相似文献

1
Pharmacokinetics of tenoxicam in patients with impaired renal function.
Eur J Clin Pharmacol. 1986;29(6):697-701. doi: 10.1007/BF00615961.
2
Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.替诺昔康在肾功能受损患者和健康志愿者中的单剂量及多剂量药代动力学、肾脏耐受性和血浆蛋白结合情况。
Pharmacol Toxicol. 2001 Nov;89(5):265-72. doi: 10.1034/j.1600-0773.2001.d01-158.x.
3
A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid.吡罗昔康在血浆和滑液中的药代动力学比较。
Br J Rheumatol. 1985 Nov;24(4):351-6. doi: 10.1093/rheumatology/24.4.351.
4
The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam.食物和抗酸剂对替诺昔康单次口服剂量药代动力学的影响。
Eur J Drug Metab Pharmacokinet. 1985 Oct-Dec;10(4):309-14. doi: 10.1007/BF03189758.
5
Single and multiple dose pharmacokinetics of tenoxicam in the elderly.替诺昔康在老年人中的单剂量和多剂量药代动力学
Eur J Clin Pharmacol. 1988;35(5):563-6. doi: 10.1007/BF00558254.
6
Effects of tenoxicam on renal function and the disposition of inulin and p-aminohippurate in healthy volunteers and patients with chronic renal failure.替诺昔康对健康志愿者和慢性肾衰竭患者肾功能及菊粉和对氨基马尿酸排泄的影响。
Br J Clin Pharmacol. 1991 Oct;32(4):495-500. doi: 10.1111/j.1365-2125.1991.tb03937.x.
7
Clinical pharmacokinetics of tenoxicam.替诺昔康的临床药代动力学
Clin Pharmacokinet. 1994 Jan;26(1):16-43. doi: 10.2165/00003088-199426010-00003.
8
Lack of effect of tenoxicam on glibornuride kinetics and response.替诺昔康对格列本脲动力学及反应无影响。
Br J Clin Pharmacol. 1985 Feb;19(2):249-54. doi: 10.1111/j.1365-2125.1985.tb02638.x.
9
The influence of cholestyramine on the elimination of tenoxicam and piroxicam.消胆胺对替诺昔康和吡罗昔康消除的影响。
Eur J Clin Pharmacol. 1988;34(3):283-9. doi: 10.1007/BF00540957.
10
The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.
Eur J Clin Pharmacol. 1992;43(2):197-9. doi: 10.1007/BF01740671.

引用本文的文献

1
Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen.两种布洛芬口服制剂解热作用的药代动力学-药效学建模
Clin Pharmacokinet. 2000 Jun;38(6):505-18. doi: 10.2165/00003088-200038060-00004.
2
Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.昔康类非甾体抗炎药的药代动力学
Clin Pharmacokinet. 1994 Feb;26(2):107-20. doi: 10.2165/00003088-199426020-00004.
3
Clinical pharmacokinetics of tenoxicam.替诺昔康的临床药代动力学

本文引用的文献

1
Kinetics of single doses of fenbufen in patients with renal insufficiency.肾功能不全患者单次服用芬布芬的药代动力学。
Clin Pharmacol Ther. 1981 Jan;29(1):74-80. doi: 10.1038/clpt.1981.13.
2
Pharmacokinetics of naproxen in subjects with normal and impaired renal function.萘普生在肾功能正常和受损受试者中的药代动力学。
Eur J Clin Pharmacol. 1980 Oct;18(3):263-8. doi: 10.1007/BF00563009.
3
Kinetics of indoprofen in patients with renal insufficiency (a preliminary report).吲哚美辛在肾功能不全患者中的动力学(初步报告)。
Clin Pharmacokinet. 1994 Jan;26(1):16-43. doi: 10.2165/00003088-199426010-00003.
4
Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.替诺昔康。对其药效学、药代动力学特性及治疗效果的初步综述。
Drugs. 1987 Sep;34(3):289-310. doi: 10.2165/00003495-198734030-00001.
5
Single and multiple dose pharmacokinetics of tenoxicam in the elderly.替诺昔康在老年人中的单剂量和多剂量药代动力学
Eur J Clin Pharmacol. 1988;35(5):563-6. doi: 10.1007/BF00558254.
6
Plasma tenoxicam concentrations after single and multiple oral doses.
Eur J Drug Metab Pharmacokinet. 1989 Jan-Mar;14(1):23-7. doi: 10.1007/BF03190838.
7
An assessment of tenoxicam, a nonsteroidal anti-inflammatory drug of long half-life, in patients with impaired renal function suffering from osteoarthritis or rheumatoid arthritis.对半衰期较长的非甾体抗炎药替诺昔康在患有骨关节炎或类风湿性关节炎的肾功能受损患者中的评估。
Clin Rheumatol. 1989 Dec;8(4):453-60. doi: 10.1007/BF02032096.
8
Pharmacokinetics of newer drugs in patients with renal impairment (Part I).肾功能损害患者中新型药物的药代动力学(第一部分)。
Clin Pharmacokinet. 1991 Apr;20(4):293-310. doi: 10.2165/00003088-199120040-00004.
9
Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases.替诺昔康。其在风湿性疾病中的药理学及治疗效果的最新进展。
Drugs. 1991 Apr;41(4):625-46. doi: 10.2165/00003495-199141040-00008.
10
The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.
Eur J Clin Pharmacol. 1992;43(2):197-9. doi: 10.1007/BF01740671.
Eur J Rheumatol Inflamm. 1981;4(1):16-21.
4
Pharmacokinetics of ketoprofen in patients with chronic renal failure.酮洛芬在慢性肾衰竭患者中的药代动力学。
Scand J Rheumatol. 1981;10(3):189-92. doi: 10.3109/03009748109095297.
5
[Inter- and intra-individual variations on the disposition of piroxicam. Pharmacokinetics in healthy man and the patient with renal insufficiency].[吡罗昔康处置的个体间和个体内差异。健康人和肾功能不全患者的药代动力学]
Pharm Acta Helv. 1982;57(1):20-6.
6
Nonsteroidal antiinflammatory drugs (second of two parts).非甾体抗炎药(两部分中的第二部分)
N Engl J Med. 1980 May 29;302(22):1237-43. doi: 10.1056/NEJM198005293022206.
7
Pharmacokinetics of piroxicam in man.吡罗昔康在人体中的药代动力学。
Eur J Rheumatol Inflamm. 1983;6(1):46-55.
8
Pharmacokinetics of isoxicam in man following oral administration.口服给药后异恶酰胺在人体内的药代动力学。
Arzneimittelforschung. 1983;33(4):582-6.
9
Determination of tenoxicam, and the isolation, identification and determination of Ro 17-6661, its major metabolite, in human urine.
J Chromatogr. 1984 Dec 28;317:483-92. doi: 10.1016/s0021-9673(01)91688-7.
10
Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.非甾体抗炎药的临床药代动力学
Clin Pharmacokinet. 1983 Jul-Aug;8(4):297-331. doi: 10.2165/00003088-198308040-00003.